ENZON PHARMACEUTICALS, INC. 8-K

What Happened

• On March 25, 2026, Enzon Pharmaceuticals, Inc. announced via press release that it has completed the exchange offer relating to its Series C Non‑Convertible Redeemable Preferred Stock. The press release is attached to the Form 8‑K as Exhibit 99.1 and is incorporated by reference.

Key Details

• Date of disclosure: March 25, 2026.
• Event: Completion of the exchange offer for Series C Non‑Convertible Redeemable Preferred Stock.
• Exhibit: Press release included as Exhibit 99.1 (incorporated by reference to Amendment No. 9 to the Schedule TO‑I/A filed March 25, 2026).
• Regulatory note: The press release and related information are furnished under Item 7.01 and, per General Instruction B.2 of Form 8‑K, are not deemed “filed” for purposes of Section 18 of the Exchange Act.

Why It Matters

• This filing tells investors that the company has completed a capital-structure transaction (an exchange offer involving Series C preferred shares). That can affect the company’s outstanding preferred securities, rights attached to them, and overall capitalization.
• Investors should review the attached press release and the referenced Schedule TO amendment for the full economic terms and any impacts on ownership, dividends, redemption rights or potential dilution. The 8‑K itself furnishes the announcement but does not include further financial statements or detailed transaction economics.